- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Hemogenyx Pharmaceuticals PLC Announces Final Results | 198 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 30.04. | Hemogenyx Pharma Plc - Final Results | 3 | RNS | ||
| 28.04. | Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise | 178 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 28.04. | Hemogenyx Pharma Plc - Institutional Fundraise | 3 | RNS | ||
| 14.04. | Hemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDA | 286 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 14.04. | Hemogenyx Pharma Plc - Annual IND Report with FDA | 1 | RNS | ||
| 31.03. | Hemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial Update | 138 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 31.03. | Hemogenyx completes tech transfer for CAR-T therapy to CDMO | 4 | Investing.com | ||
| 31.03. | Hemogenyx: Technologietransfer für CAR-T-Therapie erfolgreich abgeschlossen | 2 | Investing.com Deutsch | ||
| 31.03. | Hemogenyx Pharma Plc - Tech Transfer Completion and Clinical Trial Update | 2 | RNS | ||
| 27.02. | Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights | 294 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / February 27, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the... ► Artikel lesen | |
| 27.02. | Hemogenyx Pharma Plc - Total Voting Rights | 3 | RNS | ||
| 23.02. | Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity | 268 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 23.02. | Hemogenyx Pharma Plc - Exercise of Warrants and Issue of Equity | 1 | RNS | ||
| 10.02. | Hemogenyx Pharmaceuticals PLC Announces Issue of Equity | 562 | ACCESS Newswire | The sentence "through a direct subscription for 313,333 new ordinary shares in the Company at a price of £7.50 per share" has been corrected to "through a direct subscription for 333,333 new ordinary... ► Artikel lesen | |
| 10.02. | Hemogenyx Pharma Plc - Issue of Equity - Correction | 2 | RNS | ||
| 10.02. | SMALL-CAP WINNERS & LOSERS: Hemogenyx raises funds for phase I trials | 4 | Alliance News | ||
| 10.02. | Hemogenyx Pharma Plc - Issue of Equity | 1 | RNS | ||
| 30.01. | Hemogenyx Pharma Plc - Total Voting Rights | - | RNS | ||
| 22.12.25 | Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares | 335 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 2,120 | -10,55 % | KURSZIEL ANGEHOBEN bei InnoCan Pharma: Was große Adressen heute bereits wissen - Meine Analyse im Detail | ||
| NOVERIS HEALTH SCIENCES | 0,985 | 0,00 % | Noveris Health Sciences Inc: Noveris shareholder Bartch disposes of shares | ||
| PEAKBIRCH COMMERCE | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.02.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 02.02.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.02.2026ISIN NameCA70470T2092 PEAKBIRCH... ► Artikel lesen | |
| BAYER | 38,980 | +0,18 % | Bayer: Glyphosat-Urteile lassen Anleger zittern trotz überraschend starkem Quartal | Bayer hat mit starken Quartalszahlen den Erwartungen der Analysten getrotzt, doch die Unsicherheit durch die anstehenden Glyphosat-Urteile in den USA bleibt der große Bremsklotz für die Aktie. Während... ► Artikel lesen | |
| MERCK KGAA | 129,50 | +2,45 % | BARCLAYS stuft MERCK KGAA auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Merck KGaA mit einem Kursziel von 130 Euro auf "Equal Weight" belassen. Das erste Quartal des Pharma- und Chemiekonzerns... ► Artikel lesen | |
| NOVO NORDISK | 38,245 | +0,54 % | Novo Nordisk: Erste Früchte der Investitionsoffensive - trägt die Story trotz Wachstumsrally noch weiter? | Novo Nordisk hat im ersten Quartal 2024 eindrucksvoll unter Beweis gestellt, dass die massiven Investitionen in Produktionskapazitäten beginnen, sich auszuzahlen. Trotz hoher Bewertungskennzahlen sehen... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 83,24 | 0,00 % | Bright Minds Biosciences GAAP EPS of -$1.09 for three months ended March 31 | ||
| ETON PHARMACEUTICALS | 34,990 | -0,03 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,980 | 0,00 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 0,513 | -0,64 % | Sunshine Biopharma Inc.: Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin | FORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,230 | 0,00 % | Citizens reiterates Aquestive stock rating on Anaphylm progress | ||
| ELI LILLY | 903,40 | +0,71 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| GSK | 22,300 | +0,72 % | GSK: Japan's MHLW Expands Eligible Population For Arexvy | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include... ► Artikel lesen | |
| PFIZER | 22,380 | +0,20 % | Unterbewertet - Analysten rücken LifeScience in den Fokus! Bayer, Vidac Pharma, Novo Nordisk und Pfizer im Check | Dass Analysten den LifeScience-Bereich zuletzt wieder besser einschätzen, zeigt die dynamische Kursziel-Anpassung der DZ Bank für Bayer. Der starke Jahresstart des Pharma- und Agrarchemiekonzerns führt... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 17,240 | +0,29 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen |
HEMOGENYX PHARMACEUTICALS PLC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 7,600 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOGENYX PHARMACEUTICALS PLC finden Sie auf Wallstreet Online.